EP1714153A2 - Von gp41 abgeleitetes polypeptid, das polypeptid enthaltende impfstoffzusammensetzung sowie verwendungen zur behandlung einer hiv-virusinfektion in einem individuum - Google Patents

Von gp41 abgeleitetes polypeptid, das polypeptid enthaltende impfstoffzusammensetzung sowie verwendungen zur behandlung einer hiv-virusinfektion in einem individuum

Info

Publication number
EP1714153A2
EP1714153A2 EP05715302A EP05715302A EP1714153A2 EP 1714153 A2 EP1714153 A2 EP 1714153A2 EP 05715302 A EP05715302 A EP 05715302A EP 05715302 A EP05715302 A EP 05715302A EP 1714153 A2 EP1714153 A2 EP 1714153A2
Authority
EP
European Patent Office
Prior art keywords
cells
polypeptide
hiv
amino acid
nkp44l
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05715302A
Other languages
English (en)
French (fr)
Inventor
Vincent Vieillard
Patrice Debre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/001106 external-priority patent/WO2004070385A1/en
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Assistance Publique Hopitaux de Paris APHP
Priority to EP05715302A priority Critical patent/EP1714153A2/de
Priority claimed from PCT/EP2005/001395 external-priority patent/WO2005076001A2/en
Publication of EP1714153A2 publication Critical patent/EP1714153A2/de
Withdrawn legal-status Critical Current

Links

Definitions

  • a polypeptide derived from gp41 a vaccine composition comprising said polypeptide, and uses for treating an infection by an HIV virus in an individual FIELD OF THE INVENTION
  • the present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
  • HIV Human Immunodeficiency Viruses
  • AIDS disease which is primarily caused by infection of individuals with a HIV retrovirus, is now the most devastating disease in the whole world, since the number of individuals which are, to date, infected with HIV viruses is estimated to about 40 millions of individuals. During the sole year 2001 , 5 millions of individuals were infected with HIV while 3 millions of individuals have deceased in the same time. Since the discovery of the main AIDS causative agent in 1983, namely the HIV virus, extensive efforts have been made in order to understand the mechanism of action of this virus and to develop accurate methods for (i) reproducibiy diagnosing the infection, as well as (ii) carrying out a prognosis of the progression of the disease in a given patient.
  • CDC United States Centers for Disease Control
  • AIDS-indicator conditions such as KS, PCP or disseminated MAC.
  • KS AIDS-indicator conditions
  • PCP disseminated MAC.
  • lymphoid interstitial pneumonitis and recurrent bacterial infections are included in the list of AIDS-defining conditions (CDC, 1987b).
  • the case definition in adults and adolescents was expanded in 1993 to include HIV infection in an individual with a CD4 + T cell count less than 200 cells per cubic millimeter (mm 3 ) of blood (CDC, 1992).
  • CD4 + T cell killing have been observed in lentivims systems in vitro and may explain the progressive loss of these cells in HIV-infected individuals (reviewed in Garry, 1989; Fauci, 1993a; Pantaleo et al., 1993a). These mechanisms include disruption of the cell membrane as HIV buds from the surface (Leonard et al., 1988) or the intracellular accumulation of heterodisperse RNAs and unintegrated DNA (Pauza et al., 1990; Koga et al., 1988). Evidence also suggests that intracellular complexing of CD4 and viral envelope products can result in cell killing (Hoxie et al., 1986).
  • autoimmune phenomena may also contribute to CD4 + T cell death since HIV envelope proteins share some degree of homology with certain major histocompatibility complex type II (MHC-II) molecules (Golding et al., 1989; Koenig et al., 1988).
  • MHC-II major histocompatibility complex type II
  • superantigens either encoded by HIV or derived from unrelated agents, may trigger massive stimulation and expansion of CD4 + T cells, ultimately leading to depletion or anergy of these cells (Janeway, 1991 ; Hug et al., 1991).
  • apoptosis occurs to a greater extent in HIV-infected individuals than in non-infected persons, both in the peripheral blood and lymph nodes (Finkel et al., 1995; Pantaleo and Fauci, 1995b; Muro-Cacho et al., 1995).
  • a first current method consists of evaluating the increase in the number of HIV viruses which are present in a whole blood sample collected from a patient, for example by performing conventional immunoassays with antibodies specifically directed against HIV proteins, and more specifically against the HIV capsid glycoprotein gp120.
  • a second current method for the prognosis of progression of AIDS in a patient consists of measuring the number of copies of the HIV genome which is found in a whole blood sample collected from that patient, for example through performing a quantitative PCR amplification of the nucleic acids contained in said sample, using one or several nucleic acid primer(s) that specifically hybridise with the HIV genomic RNA.
  • a third current method for the prognosis of progression of AIDS in a patient consists of measuring the absolute CD4 + T-cell levels in whole blood samples from infected patients (HIV + patients), for example by carrying out flow cytometry from a blood sample of that patient, using a labelled antibody directed against the CD4 antigen. All of these prognosis methods above can reproducibiy be used but also have their respective technical limits, in relation with, for example, their biological significance as regards the evolution of the disease.
  • the use of antibodies for evaluating the number of HIV viral particles present in a biological sample form a patient comprise drawbacks due to the specificity of the antibodies which are used, since it is well known that the HIV structural proteins produced by distinct HIV virus isolates significantly differ in their antigenic properties and that false negative results may thus be generated.
  • the measure of the number of copies of the HIV genome in a biological sample from a patient is indeed indicative that the provirus which has integrated within the infected individual's cell genome has entered into active replication cycles and that the disease is in active progression.
  • this technique does not simultaneously reflect the patient's immune response against the virus progression.
  • the measure of the CD4 + T-cell levels in a patient is also indicative of the disease progression, since the pathogenesis of acquired immunodeficiency syndrome (AIDS) is largely attribuable to the decrease in T-lymphocytes bearing the CD4 receptor (CD4 + ). Progressive depletion of CD4 + T-lymphocytes is associated with an increase of clinical complications. Because of this association, the measurement of CD4 + T-cell levels is used to establish decision points for monitoring the relevance of treatments against AIDS. CD4 + T-lymphocyte levels are also used as prognostic indicators in patients with human immunodeficiency virus (HIV) disease.
  • HIV human immunodeficiency virus
  • the measure of the CD4 + T-cell levels in a patient does not directly reflect the immunological status of the patient, excepted as regards the resulting immunodeficiency.
  • the measure of the CD4 + T-cell levels does not account for the status of the possible biological effectors that cause or mediate the observed CD4 + depletion, and thus of the possible biological effectors that cause this observed patient's immunodeficiency.
  • a forecast of the progression of AIDS, in a given patient infected with HIV can also be carried out through the detection of mutations occurring in the amino acid sequence of known co-receptors for HIV that are expressed by the patient's cells, especially CD4 + cells, such as the CCR5 co-receptor, since it has been observed that HIV-infected people bearing a specific mutation in one of their two copies encoding the CCR5 co-receptor may have a slower disease course that people with two normal copies of this gene.
  • novel biological markers might be used in combination with one or several already known markers such as those cited above.
  • novel therapeutically useful compounds for preventing individuals from the occurrence of AIDS upon infection with a HIV virus or, more generally, for treating patients infected with a HIV virus.
  • novel anti-HIV multi-therapies or HAART Highly Active Anti-retroviral Therapy
  • novel pharmaceutically active compounds that will specifically be directed against other target molecules than the HIV protease and the HIV retrotranscriptase and which will act on targets involved in distinct stages of the disease.
  • the invention is firstly directed to a polypeptide comprising the following amino acid sequence: X 1 X 2 X 3 X4X5X6SWSNKSX 7 X8X9X ⁇ oX ⁇ (I), wherein X-i, X 2 , X3, X5, X ⁇ , X7, X ⁇ > XIO > and X-n mean, independently one from each other, any amino acid residue, X4 means any amino acid residue except A and W, and wherein X 8 means any amino acid residue except E and S.
  • compositions for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family which comprises an effective amount of a ligand compound which specifically binds to the polypeptide (I) in combination with at least one physiologically acceptable excipient.
  • the invention also deals with in vitro methods for the screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV virus, wherein said method comprises the steps of :
  • the invention is also directed to a vaccine composition comprising a polypeptide (I) and an immunoadjuvant compound. It is also directed to methods for treating HIV-infected patients that make use of the therapeutically active compounds and of the pharmaceutical compositions that are further described in the present specification.
  • FIGURES Figure 1 Over-expression of NKp44L after treatment of purified CD4+ T cells with vaccinia virus expressing several HIV proteins.
  • Purified CD4+ T cells were infected with 20 pfu/cell of several recombinant vaccinia virus expressing HIV protein. Two days later, the cells were washed twice, and stained with anti-NKp44L mAb (grey thick line), or with IgM isotype control (blak thin line). The cells were analyzed by flow cytometry. Ul: Uninfected cells., WT : cells infected with wild type vaccinia virus.
  • NKp44L expression cells infected with vaccinia virus, expressing respectively Gag, Pol, gp160, gp120, gp41 , Tat, or Nef.
  • the percentage of NKp44L expression was noted for each panel. Abscissa : NKp44L expression, Ordinates : Number of cells.
  • FIG. 1 Over-expression of NKP44L after treatment of purified CD4+ T cells with recombinant qp160 HIV protein.
  • One million of cells were incubated with 5 ug/ml of control protein (Ctl; black circle), or recombinant gp160 protein (gp160-A : black triangle) ; (gp160-B: black square) or without protein (UT: untreated cells) during 2 days in presence of 10 U/ml IL2.
  • gp160-A black triangle
  • gp160-B black square
  • UT untreated cells
  • NKp44L expression was noted for each panel. Abscissa : CD4 expression, Ordinates : NKp44L expression. 2B) NK-lysis sensitivity of CD4+ T cells incubated with recombinant gp160 HIV protein was analyzed for cytotoxic activity with activated autologous purified NK cells. NK lysis activity was performed at different effetctor/target (E T) ratios (Abscissa). Open diamonds with dotted lines: Unteated cells; Closed bottoms: Control protein-treated cells; Closed triangles: gp160-A-treated cells; and closed squares: gp160-B-treated cells. Ordinates : Specific NK lysis (%). Figure 3.
  • NK-lysis sensitivity of CD4+ T cells incubated with the different pools of peptides was analyzed for cytotoxic activity with activated autologous purified NK cells.
  • NK lysis activity was performed at different effetctor/target (E/T) ratios (Abscissa). Ordinates : Specific NK lysis (%).
  • FIG. 4 Analysis of each peptide from the pool C derived from HIV gp41 protein.
  • One million of purified CD4+ T cells were treated with 5 ug/ml of peptides from the pool C (see figure 6) (noted from C141 to C150) or as controls the peptide gp41-E162 or the peptide gp120-87. The cells were incubed two days in presence of 10 u/ml IL2, and then washed twice.
  • 4A Killing pattern of CD4+ T cells incubated with the different peptides were tested for their sensitivity to NK. Data are shown for an E/T ratio of 40/1 with activated autologous purified NK effector cells. Ordinates : Specific NK lysis (%).
  • 4B) The cells were stained with anti-NKp44L mAb and CD4 mAb or with isotype controls and analyzed by flow cytometry. Ordinates : Expression of NKp44L.
  • SWSNKS control 1 : Ctl1
  • NK-lysis sensitivity of CD4+ T cells incubated with the different peptides was analyzed for cytotoxic activity with activated autologous purified NK cells.
  • NK lysis activity was performed at different effetctor/target (E/T) ratios (Abscissa). Open diamonds with dotted lines:
  • Abscissa NKp44L expression
  • Ordinates CD4 expression.
  • NKp44L NKp44L
  • B NKp44L
  • FIG. 1 Cell surface expression of NKp44L of different human cells Cell surface expression of NKp44L of K562, Jurkat, and resting
  • Figure 8 Identification of #7.1 , an anti-NKp44L mAb that specifically inhibits NKp44-mediated NK lysis.
  • Uninfected (Ul) and HIV- 1 -infected (Sf2) U2 cells were incubated with 1 ⁇ g/ml of #7.1 mAb (black line) or with the IgM isotype control (dotted line) and analyzed by flow cytometry. (C) #7.1 mAb inhibits NKp44-lg binding.
  • HIV-1 -infected U2 cells that had previously been stained with either 10!mg of NKp44-lg fusion protein (lower panel; black line) or control NKp46-lg fusion protein (upper panel; black line) were incubated with #7.1 mAb (gray line) or IgM isotype control (dotted line) for 1 !h at 4°C and washed twice in 1 % PBS- BSA. The cells were then analyzed by flow cytometry. Percentage of cells expressing NKp44L, after NCR-lg incubation, is noted. (D) Inhibition of natural cytotoxicity by #7.1 mAb.
  • NK cells cultured in the presence of 100 U/ml IL2, were analyzed for cytotoxic activity against either the uninfected U2 cells and the HIV-1 -infected U2 cell line, after treatment with 10!mg/mi of #7.1 mAb, at different effector/target cell ratios.
  • E Inhibition of natural cytotoxicity by #44/8 anti-NKp44 mAb.
  • NK cells cultured in presence of 100 U/ml IL2, were analyzed for cytotoxic activity against either the uninfected U2 cells or the HIV-1 -infected U2 cell line, after treatment with 10 ⁇ g/ml of #44/8 anti-NKp44 mAb, at different effector/target cell ratios.
  • Peptide C146 is a polypeptide consisting of the aminoacid sequence of formula (II).
  • NKp44L a specific protein, termed NKp44L is expressed by the CD4 + T-cells form HIV- infected individuals whereas this protein is not expressed by the CD4 + T- cells from individuals which are not infected with HIV.
  • the NKp44L protein is not expressed (i) in peripheral blood mononuclear cells (PBMC) from HIV-infected patients that do not express the CD3 antigen, (ii) in PBMC form HIV-infected patients that express the CD3 antigen but not the CD4 antigen, nor (iii) in PBMC from HIV-infected patients expressing the CD8 antigen.
  • PBMC peripheral blood mononuclear cells
  • the expression level of the NKp44L protein is further enhanced in activated CD4 + T-cells, such as PHA-activated CD4 + T-cells, from HIV-infected individuals. Further, it has been previously found by the inventors that an increasing expression level of the NKp44L protein is correlated with the decrease in the number of CD4 + T-cells which is observed in HIV- infected patients, thus in patients undergoing a progression of AIDS. Consequently, the expression level of the NKp44L protein is indicative of the immunological status of an HIV-infected patient.
  • CD4 + T-cells from HIV-infected patients consist of specific targets for their cytolysis by Natural Killer (NK) cells, particularly activated NK cells, and especially autologous NK cells from the same patient.
  • NK Natural Killer
  • the present inventors have shown that the NK cells of an HIV-infected individual are activated specifically, through a non-MHC dependent triggering mechanism, by the autologous CD4 + T-cells that express the NKp44L protein.
  • the expression level of the NKp44L protein consists of a novel biological marker of the state of advancement of the HIV infection endowed with a very high biological significance, since it has been shown by the inventors that NKp44L expressed by the CD4 + T-cells triggers the autologous NK cells and activate these NK cells for specific cytolysis of the CD4 + T-cells, through a non-MHC dependent recognition of the CD4 + T-ceils by the activated NK cells.
  • the NKp44L protein expressed by the CD4 + T-cells of the HIV-infected patient activate the NK cells through the specific binding of the NKp44L protein to its specific receptor counterpart which is expressed at the membrane surface of the NK cells, namely the NKp44 receptor protein which has already been described by Cantoni et al. (1999) and by Vitale et al. (1998). Further, the NKp44L protein has formerly been isolated by another inventive entity and this protein has already been shown to be expressed in various kinds of tumour cell lines.
  • the NKp44L expressed by certain tumour cells has been shown to be a ligand that specifically binds to the NKp44 receptor protein cited above, which receptor protein is expressed by the NK cells, including the activated NK cells. It has also been formerly shown by this other inventive entity that the NKp44 receptor protein that is expressed by the activated NK cells might be responsible for at least part of the tumour cells cytolysis effected by the activated NK cells (unpublished information). Taken together, the results obtained by the inventors have allowed them to carry out various methods which make use of the NKp44L protein as a novel biologically relevant marker of the disease progression for individuals that are already diagnosed as having been infected by
  • HIV-1 gp41 is composed of three domains, an extracellular domain (ectodomain), a transmembrane domain and an intracellular domain (endodomain).
  • the gp41 ectodomain contains three major functional regions, i.e., the fusion peptide located at the N-terminus of gp41 , followed by two 4-3 heptad repeats adjacent to the N- and C- terminal portions of the gp41 ectodomain, designated NHR (N-terminal heptad repeat) and CHR (C-terminal heptad repeat), respectively.
  • NHR N-terminal heptad repeat
  • CHR C-terminal heptad repeat
  • Both NHR and CHR regions function as essential structures required for conformational changes during the process of membrane fusion between HIV-1 and CD4 + T cells.
  • a short peptide derived from the gp41 protein, which is located between the well-known HR1 and HR2 regions, induces the surface expression of NKp44L on CD4 + T cells.
  • the inventors have identified a short peptide derived from the gp41 protein of HIV, which is responsible for the NKp44L surface expression and thus also for the lysis of CD4+ T cells by the endogenous NK cells.
  • the present inventors have also shown that the protein NKp44L is expressed on tumor cell surface and that this expression of NKp44L is induced or enhanced by said short peptide derived from gp41.
  • said short peptide derived from gp41 can be used for expressing NKp44L at the surface of tumor cells and then induce their specific lysis by NK cells.
  • the invention concerns therapeutical methods, and pharmaceutical compositions, comprising a polypeptide as briefly described above, for manufacturing anti-cancer pharmaceutical compositions.
  • the inventors have found that antibodies directed against a polypeptide derived from the gp41 protein, are produced during HIV infection of an individual.
  • the invention concerns therapeutical methods, and vaccine compositions, comprising a polypeptide as briefly described above. It has also been found according to the invention that the level of the antibodies described above, decreases during the progression of HIV infection, especially as regards the development of the patient's immunodeficiency caused by the progressive depletion of his CD4+ T cells.
  • an object of the invention is a polypeptide comprising the following amino acid sequence : X- ⁇ X2X3X4X5X6SWSNKSX X8X9X.oX ⁇ . (I), wherein Xi, X 2 , X 3 , X5, X ⁇ , X7, X9, X10.
  • any amino acid residue designates any amino acid residue selected from the group consisting of the following amino acids : A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, and V.
  • Said polypeptide is also referred to as a polypeptide of formula (l).
  • the invention encompasses further polypeptides comprising the following amino acid sequence : PWASNASWSNKSLDDIW (II).
  • said polypeptide has a length of at least 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or 20O amino acid residues.
  • a polypeptide, as defined above, is preferably derived from the gp41 protein and possesses at least 39, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 consecutive amino acids of gp41 protein from HIV-1 and comprises the amino acid sequence of formula (I) above.
  • the polypeptide of formula (I) can be produced by recombinant DNA techniques, for example on the basis of the DNA sequence of gp41 protein from HIV1 , by using any of a variety of expression vectors known to those of ordinary skill in the art.
  • Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide.
  • Suitable host cells include prokaryotes, yeast, and higher eukaryotic cells, such as mammalian cells and plant cells.
  • the host cells employed are E. coli, yeast or a mammalian cell line such as COS or CHO.
  • Supematants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin.
  • polypeptide of formula (I) comprises less than about 100 amino acids, and generally less than about 50 amino acids, it can be generated by synthetic means, using techniques well known to those of ordinary skill in the art.
  • polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963.
  • Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City,
  • a polypeptide of formula (I) consists of the following amino acid sequence: PWASNASWSNKSLDDIW (II).
  • PWASNASWSNKSLDDIW II
  • the induction of NKp44L expression on CD4+ T-cells surface induced by the polypypetide of amino acid sequence (II) is illustrated in examples 1-3 below.
  • the high kinetics of the induction of the NKp44L expression at the cell surface is compatible with the induction of a translocation of a pre- synthesised NKp44L intracellular protein, from the cytoplasm towards the cell surface.
  • compositions according to the invention are a pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family, which comprises an effective amount of a ligand compound which specifically binds to the polypeptide of formula (I), in combination with at least one physiologically acceptable excipient.
  • physiologically acceptable excipient or carrier is meant solid or liquid filler, diluent or substance which may be safely used in systemic or topical administration.
  • a variety of pharmaceutically acceptable carriers well known in the art include solid or liquid fillers, diluents, hydrotropes, surface active agents, and encapsulating substances.
  • compositions of the invention include sugar, starches, cellulose, vegetable oils, buffers, polyols and alginic acid. Specific pharmaceutically acceptable carriers are described in the following documents, all incorporated herein by reference: U.S. Pat. No. 4,401 ,663, Buckwalter et al. issued August 30, 1983; European Patent Application No. 089710, LaHann et al. published Sept. 28, 1983; and European Patent Application No. 0068592, Buckwalter et al. published Jan. 5, 1983.
  • Preferred carriers for parenteral administration include propylene glycol, pyrrolidone, ethyl oleate, aqueous ethanol, and combinations thereof.
  • Representative carriers include acacia, agar, alginates, hydroxyalkylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, carrageenan, powdered cellulose, guar gum, cholesterol, gelatin, gum agar, gum arabic, gum karaya, gum ghatti, locust bean gum, octoxynol 9, oleyl alcohol, pectin, poly(acrylic acid) and its homologs, polyethylene glycol, polyvinyl alcohol, polyacrylamide, sodium lauryl sulfate, poly(ethylene oxide), polyvinylpyrrolidone, glycol monostearate, propylene glycol monostearate, xanthan gum, tragacanth, sorbitan esters, stearyl alcohol, starch and
  • Suitable ranges vary from about 0.5% to about 1 %.
  • the one skilled in the art will advantageously refer to the last edition of the European pharmacopoeia or of the United States pharmacopoeia.
  • the one skilled in the art will refer to the fourth edition "2002" of the European Pharmacopoeia, or also to the edition USP 25- NF20 of the United States Pharmacopoeia.
  • the weight amount of therapeutically active compound that is contained in each dose of the pharmaceutical composition of the invention will depend on the molecular weight of said therapeutically active compound as well as on the weight amount that is effective in blocking the cytolysis of the CD4+ T-cells by the NK cells in an HIV- infected patient.
  • the one skilled in the art firstly determines the in vitro CD4 + T- cell cytolysis inhibiting ability of various weight amounts or concentrations of said therapeutically active compound, for example by performing the screening method of the invention which are describe below, and then retain or select the given amount or concentration of said therapeutically active compound that blocks cytolysis. Then, the one skilled in the art transposes said retained or selected amount or concentration to the in vivo human situation, so that the concentration of said therapeutically active compound in the blood of a patient to which the pharmaceutical composition of the invention has been administered is identical to the concentration that blocks cytolysis in vitro.
  • the ligand compound consists of an antibody directed to the polypeptide according to the invention.
  • the ligand compound, or the pharmaceutical composition containing it can be combined with a compound that inhibits the membrane fusion between HIV and CD4+ T cells.
  • Such compounds are, for example, peptides derived from the HR1 or HR2 region of the gp41 protein and more precisely peptides referred to as T20, T21 or those described in US patent application 6,623,741.
  • the invention concerns also an antibody directed against a polypeptide of formula (I).
  • This invention is also directed to the use of a ligand compound which specifically binds to the polypeptide of formula (I), for manufacturing a pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family.
  • a ligand compound which specifically binds to the polypeptide of formula (I)
  • the protein NKp44L is expressed on tumor cell surface, such as Jurkat cells and K562 cells. They have also shown that a polypeptide of formula (I) induces the cell surface expression, of NKp44L by tumor ceils, which then render these polypeptide-treated tumor cells susceptible to specific lysis by the NK cells.
  • the invention concerns methods and pharmaceutical compositions, comprising a polypeptide of formula (I), for treating cancer.
  • the invention concerns a pharmaceutical composition for treating a cancer, which comprises an effective amount of an antigenic compound comprising or consisting of a polypeptide of formula (I), in combination with at least one physiologically acceptable excipient.
  • the physiologically acceptable excipients used to carry out the pharmaceutical composition described above are the same than those that are described in the first part of the specification concerning ligands of NKp44L.
  • the invention concerns also a pharmaceutical composition for treating a cancer, which comprises an effective amount of an antigenic compound comprising or consisting of a polypeptide of formula (I), fused to a targeting cancer cells, in combination with at least one physiologically acceptable excipient.
  • said compound, which targets cancer cells consists of an antibody directed to an antigen specific of cancer, such as SCP-1 , NY-ESO-1 , or SSX-2 specific of breast cancer, SSX-2, NY-ESO-1 , or MAGE-3 specific of melanoma, described in US patent 6,338,947 ; or antigens specific of renal cancers such as those described in US patent 6,440,663 ; KH-1 and N3 specific of colon cancer, described in US patent 6,238,668.
  • an antigen specific of cancer such as SCP-1 , NY-ESO-1 , or SSX-2 specific of breast cancer, SSX-2, NY-ESO-1 , or MAGE-3 specific of melanoma, described in US patent 6,338,947 ; or antigens specific of renal cancers such as those described in US patent 6,440,663 ; KH-1 and N3 specific of colon cancer, described in US patent 6,238,668.
  • Immunogenic and vaccine compositions according to the invention The inventors have found that antibodies directed against a polypeptide derived from the gp41 protein, i.e. the polypeptide of formula (I), are produced during HIV infection of an individual. More precisely, it has been found, according to the invention a statistically significant correlation between the expression level of antibodies directed the polypeptide of formula (I), collected from HIV- infected individuals and their level of CD4+ T cells. It has also been found that these antibodies inhibits the cytotoxicity of NK cells towards CD4+ T cells, in patients infected by HIV. Further, the inventors have surprisingly found that antibodies screened for their capacity to inhibit CD4+ T cells NK lysis, react specifically with NKp44L on HIV-1 infected cells (example 5).
  • NKp44 is a protein having the amino acid sequence SEQ ID N°2, encoded by a nucleic acid of sequence SEQ ID N°4. It has also been found that an antibody directed against a polypeptide of formula (I) above, inhibits NKp44L expression onto CD4+T cells surface, and by the way, decreases sensitivity to NK lysis.
  • NKp44L expression was substantially lower in purified CD4+ T cells from two HIV-1 infected patients that were incubated with an antibody directed to the polynucleotide (I), than in purified and then untreated cells or in those treated with a control Ab. (example 6, figure 9) It has also been found that the serum from patients infected by HIV, when depleted in antibodies directed against polypeptide (I) is not able to decrease the CD4+ T cells NK lysis.
  • Another object of the invention is a vaccine composition comprising a polypeptide of formula (I) and an immunoadjuvant compound.
  • a further object of the invention is an immunogenic composition comprising a polypeptide of formula (I), in combination with at least one physiologically acceptable excipient.
  • immunogenic composition it is herein intended a substance which is able to induce an immune response in an individual, and for example to induce the production of antibodies directed against the polypeptide of formula (I).
  • said immunoadjuvant compound is selected in the group consisting of Freund complete adjuvant, Freund incomplete adjuvant, aluminium hydroxide, calcium phosphate, aluminium phosphate, potassium phosphate, Cholera toxin (CT) and its B subunit (CTB), toxins from Bordetella pertusssis (PT), labile toxin (LT) from Escherichia coli, monophosphoryl lipid A, CpG oligonucleotides, imidazoquinolones, oil in water emulsions, comprising squalene and synthetic copolymers, muramyl dipeptides and their derivatives, saponins and immunostimulating complexes (ISCOMs), and dimethyldioctadecylammonium bromide or chloride (DDA).
  • CT Cholera toxin
  • CTB Cholera toxin
  • PT Bordetella pertusssis
  • LT labile toxin
  • said immunoadjuvant can be selected in the group comprising: aluminium hydroxide, aluminium phosphate, potassium phosphate, calcium phosphate, or bacteria toxins such as Cholera toxin (CT) and its B subunit (CTB), toxins from Bordetella pertusssis (PT), or labile toxin (LT) from Escherichia coli.
  • CT Cholera toxin
  • CTB Cockayne syndrome
  • PT Bordetella pertusssis
  • LT labile toxin
  • said immunoadjuant can be selected in the group comprising: monophosphoryl lipid A, CpG oligonucleotides, imidazoquinolones.
  • oil-based adjuvants such as oil in water emulsions, comprising squalene and synthetic copolymers can be used as an immunoadjuvant or also muramyl dipeptides and their derivatives.
  • polysaccharides such as dextran, mannans, glucans, or chitosans can be used as an immunoadjuvant.
  • saponins and immunostimulating complexes can be used as an immunoadjuvant.
  • a Freund complete adjuvant can be used as an immunoadjuvant.
  • the polypeptide of formula (I) can comprise from 2 to 12 peptides of formula "SWSNKS".
  • said antigenic polypeptide can have the following formula (III) :
  • PepNt consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the N-terminal end of the polypeptide of formula (III);
  • - "[(l)n-PepXn]” consists of a polypeptide unit wherein : - "(I) ⁇ " to - “(l)n” each consists of, one independently from each other, a polypeptide of formula "SWSNKS", with n being an integer from 1 to 12; and - "PepXi” to “PepX n " each consists of, one independently from the other, a spacer polypeptide having an amino acid length varying from 0 to 30 amino acid residues, with n being an integer from 1 to 12; - n is the number of [(l) n -PepX n ] polypeptide units in said polypeptide, with n being an integer from 1 to 12; and
  • PepCt consists of a polypeptide having an amino acid length varying from 0 to 100 amino acid residues and located at the C-terminal end of the polypeptide of formula (III).
  • Said antigenic polypeptide can be covalently linked through an amino acid residue to a carrier protein or a synthetic polymer.
  • the peptide of formula (I) can be covalently linked (“conjugated") to a larger molecule which serves as a carrier. Attachment of the peptide to the carrier can be by one of several methods, including linking through a peptide Lys using glutaraldehyde (Reichlin, Methods Enzymol.
  • Peptide carrier conjugates can be separated from excess free peptide by dialysis or gel filtration.
  • the level of loading of the peptide on the carrier can be determined either using a radioactive tracer to establish the loading level in a particular procedure, or by quantitative amino acid analysis of the conjugate, in comparison with the unloaded carrier.
  • Nle N-terminal or C- terminal side
  • said carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin, or diphtheria toxoid.
  • said synthetic polymer can be a multiple branch peptide construction comprising a core matrix comprised of lysine residues.
  • Radially branched systems using lysine skeletons in polymers have been used by J. P. Tarn [Proc. Natl. Acad. Sci. U.S.A., 85, 5409- 5413 (1988)] to develop antigens without the use of carriers.
  • Those antigens were designed to generate vaccines against a variety of diseases. Specifically, antigens for generating vaccines against HIV infection are described by Tarn in PCT patent application ser. no. W093/03766, and in US patent Application US5,229,490.
  • the core matrix is preferably a dendritic polymer which is branched in nature, preferably with each of the branches thereof being identical.
  • the core matrix is based on a core molecule which has at least two functional groups to which molecular branches having terminal functional groups are covalently bonded.
  • Exemplary for use to form the core matrix is lysine.
  • a central lysine residue is bonded to two lysine residues, each through its carboxyl group, to one of the amino groups of the central lysine residue.
  • This provides a molecule with four amino groups, which may be a core matrix for a structure comprising four polypeptides of formula (I).
  • the manufacture of the above structures has been know in the art. See, e.g., Tarn et al., J.
  • a peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art.
  • Suitable peptide linker sequences may be chosen based on the following factors: (1 ) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes.
  • Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence.
  • Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci.
  • the linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non- essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.
  • the invention concerns also a vaccine composition comprising a polypeptide comprising the amino acid sequence SWSNKS, said polypeptide, being covalently linked through an amino acid residue to a carrier protein or to a synthetic polymer.
  • said carrier protein is selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin, or diphtheria toxoid.
  • the synthetic polymer can be a multiple branch peptide construction comprising a core matrix comprised of lysine residues. Spacers between said polypeptide and said carrier protein or synthetic polymer can be introduced.
  • This invention is also directed to the use of an antibody directed against a polypeptide of formula (I) for manufacturing a pharmaceutical composition for treating a disease linked to the infection of an individual with a virus of the HIV family.
  • the vaccine composition according to the invention further comprises one or more components selected from the group consisting of surfactants, absorption promoters, water absorbing polymers, substances which inhibit enzymatic degradation, alcohol, organic solvents, oils, pH controlling agents, preservatives, osmotic pressure controlling agents, propellants, water and mixture thereof.
  • suitable supplementary carriers include, but are not limited to, sterile water, saline, buffers, phosphate-buffered saline, buffered sodium chloride, vegetable oils, Minimum Essential Medium (MEM), MEM with HEPES buffer, etc.
  • the vaccine composition of the invention may contain conventional, secondary adjuvants in varying amounts depending on the adjuvant and the desired result.
  • the customary amount ranges from about 0.02% to about 20% by weight, depending upon the other ingredients and desired effect.
  • suitable secondary adjuvants include, but are not limited to, stabilizers; emulsifiers; aluminum hydroxide; aluminum phosphate; pH adjusters such as sodium hydroxide, hydrochloric acid, etc.; surfactants such as Tween.RTM. 80 (polysorbate 80, commercially available from Sigma Chemical Co., St.
  • liposomes arecom adjuvant; synthetic glycopeptides such as muramyl dipeptides; extenders such as dextran or dextran combinations, for example, with aluminum phosphate; carboxypolymethylene; bacterial cell walls such as mycobacterial cell wall extract; their derivatives such as CoiNnebacterium parvum; Propionibacterium acne; Mycobacterium bovis, for example, Bovine Calmette Guerin (BCG); vaccinia or animal poxvirus proteins; subviral particle adjuvants such as orbivirus; cholera toxin; N,N- dioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine (avridine); monophosphoryl lipid A; dimethyldioctadecylammonium bromide (DDA, commercially available from Kodak, Rochester, N.Y.); synthetics and mixtures thereof.
  • synthetic glycopeptides such as muramyl dipeptides
  • aluminum hydroxide is admixed with other secondary adjuvants or an immunoadjuvant such as Quil A.
  • suitable stabilizers include, but are not limited to, sucrose, gelatin, peptone, digested protein extracts such as NZ-Amine or NZ-Amine AS.
  • emulsifiers include, but are not limited to, mineral oil, vegetable oil, peanut oil and other standard, metabolizable, non-toxic oils useful for injectables or intranasal vaccines compositions. These adjuvants are identified herein as "secondary" merely to contrast with the above-described immunoadjuvant compounds.
  • preservatives can be added to the vaccine composition in effective amounts ranging from about 0.0001 % to about 0.1 % by weight. Depending on the preservative employed in the formulation, amounts below or above this range may be useful. Typical preservatives include, for example, potassium sorbate, sodium metabisulfite, phenol, methyl paraben, propyl paraben, thimerosal, etc.
  • the choice of inactivated, modified or other type of vaccine composition and method of preparation of the improved vaccine composition formulation of the present invention are known or readily determined by those of ordinary skill in the art.
  • the vaccine composition accordinging to the invention, a pharmacologically effective amount of the immunoadjuvant compound described above may be given, for example orally, parenterally or otherwise, concurrently with, sequentially to or shortly after the administration of the polypeptide of formula (1).
  • the vaccine composition of the present invention is conveniently administered orally, parenterally (subcutaneously, intramuscularly, intravenously, intradermally or intraperitoneally), intrabuccally, intranasally, or transdermally.
  • the invention also concerns a first method for the in vitro screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV virus, comprising the steps of : (i) incubating a candidate compound to be tested with a polypeptide of formula (I), (ii) assaying for the binding of the candidate compound to be tested with a polypeptide of formula (I).
  • step (ii) consists of subjecting to a gel migration assay the mixture obtained at the end of step (i) and detecting the complexes formed between the candidate compound and the polypeptide of formula
  • the gel migration assay can be carried out as known by the one skilled in the art.
  • the detection of the complexes formed between the complexes formed between the candidate compound and the polypeptide according to the invention can be easily observed by determining the stain position (protein bands) corresponding to the proteins analysed since the apparent molecular weight of a protein changes if it is part of a complex with another protein.
  • the stains (protein bands) corresponding to the proteins submitted to the gel migration assay can be detected by specific antibodies for example antibodies specifically directed against a polypeptide of formula (I).
  • a polypeptide of formula (I) can be tagged for an easier detection of the protein/candidate compound on the gel.
  • the polypeptide according to the invention can be fused to GST, HA, a poly-Histidine chain, or other detectable molecules in order to facilitate the identification of the different proteins on the gel.
  • the invention further concerns a second method for the in vitro screening of compounds for preventing or treating a disease linked to the infection of an individual with an HIV virus, comprising the steps of: a) (i) bringing into contact a first CD4+ T-cell culture with a candidate compound, and HIV virus ; (ii) bringing into contact a second CD4+ T-cell culture with HIV virus, in the absence of said candidate compound ; and b) detecting the presence of NKp44L at the CD4+ T-cells surface issued from the culture (i) and (ii).
  • the detection of the presence of NKp44L at the CD4+ T-cells surface can be carried out as known by the one skilled in the art, for instance by a cytofluorometric analysis as it is described in the part Material and methods, corresponding to the example 6.
  • the method described above comprises an additional step (c) which consists of selecting positively the candidate compound as a therapeutical agent when the level of expression of NKp44L at the CD4+ T-cells surface issued from the culture (ii) is higher than the level of expression of NKp44L at the CD4+ T-cells surface issued from the culture (i).
  • CD4+ T-cells surface can be assessed by counting the number of CD4+ T cells expressing NKp44L on their surface, using a fluorescence activated cell sorter (FACS), as described in the corresponding Material and Methods section. Alternatively, the detection of the presence of NKp44L at the
  • CD4+ T-cells surface can be carried out indirectly, by measuring the NK lysis activity of CD4+ T cells, as it is described in the section Material and
  • This particular embodiment of the step (b) of the screening method above despite it consists of an in vitro method, has the technical advantage to directly reflect the therapeutical potential of the candidate compound by directly evidencing the biological activity of said candidate compound, as regards preventing the CD4 + T-cells cytolysis by the activated NK cells.
  • the activated NK cells may consist of cells from a NK cell line, such as the NK92 cell line described by Gong et al. (1994) or may consist of a primary culture of normal human purified NK cells.
  • the CD4 + T-cells that express the NKp44L protein may consist of
  • CD4 + T-cells eventually under the form of a cell line, that have been transfected with a vector that allow the expression by said cells of the NKp44L protein, or may consist of CD4 + T-cells that were initially purified from a blood sample of an HIV-infected patient.
  • the activated NK cells and the CD4 + T-cells are autologous in that they both come from the same HIV-infected patient.
  • the cytolysis measure consists of the conventional technique wherein the CD4 + T-cells, which are the target cells, are initially rendered radioactive with 51 Cr, and wherein the cytolysis value consists of the percentage of cell lysis, as measured by the amount of
  • the cytolysis value is obtained by assaying the cytolytic activity of the NK cells at increasing effector (NK cells) to target
  • Candidate compounds for use in the screening methods described immediately above can be selected among the candidate compounds which binds to one or several polypeptides of formula (I). Accordingly, the invention also concerns a method for the in vitro screening of compounds for preventing or treating a disease linked with the infection of an individual with an HIV virus, comprising the steps of : (i) submitting a candidate compound to the first screening method above, and
  • step (ii) submitting a candidate compound positively selectionned at step (i) to the second screening method described immediately above.
  • the expression level said antibodies consists of a novel biological marker of the state of advancement of the HIV infection endowed with a very high biological significance, since it has been shown by the inventors that the level of antibodies directed against polypeptide (I) is more important at the beginning of infection of a patient by HIV. Accordingly, the invention also concerns a method for the in vitro assessment of the progression status of the infection of an individual with an HIV virus, wherein said method comprises the step of detecting in a sample from said individual, antibodies directed against a polypeptide of formula (I).
  • an “HIV” virus consists of either an HIV-1 or an HIV-2 virus, and more particularly any virus strain or isolate of an HIV-1 or an HIV-2 virus.
  • the "assessment of the progression status" of the infection consists of raw experimental data indicative of the immunological status of the HIV-infected patient tested; Hence, as already mentioned above, there is a statistically relevant correlation between the amount of antibodies directed against the polypeptide of formula (I) and the CD4+ T cells count. The sole detection of antibodies directed against a polypeptide of formula (I) might not be sufficient for a global accurate clinical diagnosis, or prognosis, of the progression status of the disease within the patient tested.
  • the detection of antibodies directed against a polypeptide of formula (I) might be completed by, or combined with, other diagnosis or prognosis markers of the disease, for example one of the prior art markers that have previously been cited in the present specification.
  • the detection of antibodies directed against a polypeptide of formula (I) can be achieved using known techniques such as ELISA or RIA tests.
  • This invention also deals with a method for preventing or for treating a disease linked to the infection of an individual with a virus of the HIV family, wherein said method comprises a step of administering to a patient in need of such treatment an effective amount of an immunogenic or a vaccine composition comprising a polypeptide of formula (i) in combination with an immunoadjuvant coompound.
  • said method comprises the following steps : - preparing a purified batch (HPLC, > 95%) of polypeptide comprising the aminoacid sequence (II), linked to diphteria toxoid, - Injecting diphteria toxoid alone to a first "control" group of mammals - Injecting the polypeptide comprising the aminoacid sequence (II), linked to diphteria toxoid, to a second "test" group of mammal,
  • the mammals used are of the Macaca mulatta species, they received 0,5 mg per mammal, and per injection of diphteria toxoid, linked or not, to the polypeptide cited above, followed by 3 new injections 3, 6 or 9 weeks later, in combination with Freund's incomplete adjuvant, - infecting the two groups of mammals with SHIV33, two weeks after the last injection, with 1 ml of a dilution at 50 TCID50/ml.
  • PBMC peripheral blood mononuclear cells
  • analyses can comprises, without limitation, the control of the general aspect of the sample, the measurement of the amount of CD4+ T cells using a FACS, the measurement of the viral load by RT-PCR, the determination of the seroconversion by detecting antibodies directed against Env protein by EIA technique, the detection of antibodies directed against polypeptide of formula (II) by ELISA.
  • analyses can comprise also the study of the effects of antibodies produced by said mammals on cells infected by HIV, and for example chronically infected cells. These cells are for example, U2 cells infected by HIV-sf2, Jurkat cells infected by HIV-BRU, or CD4+ T cells infected by BRU or collected from HIV infected patients. Further, these analyses can comprise the measurement of
  • NKp44L expression level by FACS, the analysis of P24 amount, by EIA, or the analysis of NK cytotoxic activity of several strains of NK cells, such as autologous or allogenic NK92, NK3.3, or NKL cells, using a 5 Cr test as described below.
  • a further object of the invention consists of a method for preventing or for treating a disease linked to the infection of an individual with a virus of the HIV family, wherein said method comprises a step of administering to a patient in need of such treatment an effective amount of an antibody directed against the polypeptide of formula (I)
  • the invention concerns also the use of a ligand compound which specifically binds to the polypeptide of formula (I), for manufacturing a pharmaceutical composition for preventing or treating a disease linked to the infection of an individual with a virus of the HIV family.
  • the invention also deals with the use of a polypeptide of formula (I), for manufacturing a vaccine composition for treating a disease linked to the infection of an individual with a virus of the HIV family.
  • the present invention is further illustrated by, without in any way being limited to, the following examples.
  • A.1 HIV-1 infected donors Blood samples of 25 HIV-1 -infected patients were obtained from consenting donors at H ⁇ pital Pitie-Salpetriere. Bio-clinical examinations included routine determinations of the viral load, total blood and CD4 + T lymphocyte counts. As control group, Blood samples from 20 uninfected donors were obtained by leukapheresis from the blood bank (H ⁇ pital Pitie-Salpetriere).
  • A.2 Cytofluorometric analysis A three-colors FACS analysis was performed on freshly harvested PBMC. Isotype-matched immunoglobulin served as the negative control (BD). Cells were incubated 1h at 4°C, with the appropriate cocktail of antibodies.
  • Anti-CD3; anti-CD4; anti-CD8, anti-CD56, anti-NKp44, anti- NKp46 or anti-NKp44L mAb were lysed using the FACS lysing solution (BD). A minimum of 20,000 leucocytes was analyzed on a FACScan, as previously described. To measure the expression of cell surface activation markers,
  • PBMC peripheral blood mononuclear cells
  • T CD4* cells expressing NKp44L CD4 + T cell subset sorting was performed using the
  • CD4 + T expressing NKp44L were positively selected by a two step magnetic separation, CD4 + T cells were incubated with 10 ⁇ g/ml of anti-NKp44L for 1-h at RT, followed by treatment with goat anti IgM mouse-coated Dynabeads (Dynal) at a bead-to-cell ratio of 10:1 for 30 min at RT. The cell fraction purity was determined by FACS analysis.
  • NK lines were generated from PBMC, and then purified using the StemSep cell separation system and the NK cell enrichment antibody cocktail (StemCell technologies). NK purified cells were cultured in MyeloCuIt H5100 medium (StemCell technologies) supplemented with 100 units rhlL-2 (Boheringer). The purity of these preparations was evaluated by flow cytometry after staining with anti-CD3 (BD), anti-CD56 (BD), anti-NKp44, and anti-NKp46 mAbs. The cytolytic activity was assayed in 4-h 51 Cr-release assay as previously described.
  • the target cells were labeled for 2-h at 37°C with 100 ⁇ Ci per 10 6 cells Na 51 Cr (Amersham), and washed twice with culture medium.
  • the target cells were then distributed in round-bottomed 96-well microtiter plates (4 x 10 3 cells per well), and the effector cells were added at several E/T rario.
  • the plates were incubated 4-h at 37°C.
  • the supernatant were then collected and 51 Cr-release was measured in a gamma counted. In experiments in which Abs were included, these were added to final concentration of 20 ⁇ g/ml.
  • the relative specific 5 Cr- release was calculated according to conventional methods.
  • RosetteSepCD4 + enrichment kit (StemCell). The cell fraction purity was determined by FACS analysis.
  • B.2 Cvtofluorometric analysis A two-colors FACS analysis was performed on purified CD4+ T cells. Isotype-matched immunoglobulin served as the negative control (BD). Cells were incubated 1h at 4°C, with the appropriate cocktail of antibodies. anti-CD4 or anti-NKp44L mAb. A minimum of 20,000 CD4+ T cells was analyzed on a FACScan, as previously described. The intracellular expression of NKp44L was realized as previously described, briefly, the cells were incubated in 4% PFA buffer for 20 min, then washed in stained in presence of 0.1 % saponin/PBS/1 % BSA buffer at 4°C. the cells were then analyzed by FACS.
  • NK lines were generated from PBMC, and then purified using the
  • NK purified cells were cultured in MyeloCult H5100 medium (StemCell technologies) supplemented with 100 units rhlL-2 (Boheringer). The purity of these preparations was evaluated by flow cytometry after staining with anti-CD3 (BD), anti-CD56 (BD), anti-NKp44, and anti-NKp46 mAbs.
  • the cytololytic activity was assayed in 4-h 51 Cr-release assay as previously described. Briefly, the target cells were labeled for 2-h at 37°C with 100 ⁇ Ci per 10 6 cells Na 51 Cr (Amersham), and washed twice with culture medium. The target cells were then distributed in round-bottomed 96-well microtiter plates (4 x 10 3 cells per well), and the effector cells were added at several E/T rario. The plates were incubated 4-h at 37°C. The supernatant were then collected and 5 Cr-release was measured in a gamma counted. In experiments in which Abs were included, these were added to final concentration of 20 ⁇ g/ml. The relative specific 51 Cr- release was calculated as previously described.
  • Anti-NKp44 (44/8; lgG1 ) and anti-NKp44L mAb (#7.1 ; IgM) were obtained from 5-weekold BalB/c mice immunized with the ClonaCell-HY hybridoma cloning kit, according to the manufacturer's instructions (StemCell Technologies Inc.). The anti-mouse-peroxidase hybridoma screening reagent (Roche) and ELISA were used to select antibodies.
  • Anti-NKp44 (44/8) mAb was prepared by immunizing the mice with NKp44-lg protein, after specific deletion of the lgG1 human Fc fragment.
  • mice were immunized with acid-treated U2-sf2 cells. These cells were prepared as previously described (S. Sumitran- Karuppan , E. Moller, Transpl. Immunol. 4, 163, 1996.). Briefly, one million U2-Sf2 cells were washed 3 times in PBS and treated for 5 min on ice in an acid buffer prepared by mixing equal volumes of 0.263 M citric acid and 0.123 M Na2HPO4 containing 1% (w/v) BSA. After three more washes, the cells were resuspended in PBS and then irradiated and injected into the mice.
  • hybridomas were analyzed with 51 Cr cytotoxic assays with untreated or acid-treated 721.221 cells as targets, and the specificity of the anti-NKp44 hybridoma was analyzed by ELISA with different fusion proteins.
  • the #7.1 mAb (IgM) mAb was purified on a mannan-binding protein (MBP) column (Pierce), after ammonium sulfate precipitation (50% saturated solution); the anti-NKp44 mAb was purified on a protein A/G column (Pierce). The purity of each purified mAb was confirmed on SDS -PAGE.
  • Example 1 Effects of several HIV viral proteins on NKp44L expression
  • the effect of HIV viral protein on NKp44L expression was examined using infection with recombinant vaccinia virus expressing HIV viral protein.
  • the expression of NKp44L was markedly enhanced in CD4+ T cells infected with vaccinia virus expressing the gp160 (33,9%) or the gp41 HIV Env proteins (35,6%).
  • neither other HIV proteins tested like Gag, Pol, Tat, nef, vif, or gp120, influenced the cell surface expression of NKp44L protein.
  • the role of the Env protein to enhance the expression of NKp44L was confirmed in a non-viral system.
  • gp160 recombinant gp160 protein provided of two different origins, and as shown in Figure 2A, these gp160 recombinant proteins influenced the expression of NKp44L. Indeed, 10,7% and 9,6% of CD4+ T cells expressed NKp44L after treatment with the gp160-A and gp160-B, respectively. On the other hand, no effect was observed with untreated cells or cells incubated with a control protein. All together, these results show that the recombinant gp160 protein markedly enhances the cell surface expression of NKp44L on CD4+ T-cells surface.
  • Example 2 gp160 induces the NK lysis of CD4+ T cells.
  • NK lysis activity from the untreated cells, the cells treated with the control protein or the cells treated with the both recombinant gp160 proteins shows that target cell lysis was increased in the presence of CD4+ T cells cultured with recombinant gp160 protein.
  • the use of two different types of recombinant gp160 proteins indicates that the procedure used to induce over-expression of NKp44L and increased of NK lysis activity had no influence on the outcome of the experiments. Together, these results indicate that gp41 HIV Env protein was required for the over-expression of NKp44L correlated with a strong increased of NK lysis activity.
  • CD4+ T cells were incubated with 5 ⁇ g of each pool of peptides and tested against activated NK cells. As shown in Figure 3, NK lysis was increased in cells incubated with the pool of peptides named gp41C, but not with all of the other pool of peptides.
  • the expression of NKp44L in purified CD4+ T cells treated with each of the pool of peptides has been tested. This receptor was only detectable in cells treated with pool gp41 C, and the percentage of positive cells was 13,3%.
  • NKp44L was detected on the cells incubated with the other pool of peptides tested. This suggested that one or several peptide motifs included in the pool gp41C was directly implicated in the increased of NK lysis via the over-expression of NKp44L. Repeated experiments with all of the peptides included in the pool gp41 C was then tested. As shown in Figure 4A, the NK cytotoxic activity was strongly increased in presence of the peptides gp41-C145, gp41-C146, and gp41-C147. By contrast, with the other peptides tested, the NK lysis activity remained low, closed to the background.
  • NKp44L was increased after pretreatment of CD4+ T cells with the peptides gp41-C145, gp41- C146, and gp41-C147, with a percentage of positive cells varied between 22 and 16%, but not with the other peptides (less than 7% of positive cells) (Figure 4B).
  • NKp44L+ cells were less than 4% in untreated cells or cells treated by the control peptides.
  • NH2-SWSNKS-COOH motif included in the gp41 protein is strongly implicated in the NK lysis of CD4+ T cells.
  • the effect of gp41 peptide is time dependant ( Figure 6). NK lysis activity started after 30 min of incubation with the WT peptide and approached a maximum closed to 4-days. On the other hand, no significant effect is observed after treatment with the untreated cells or the cells treated with the control peptides.
  • NK lysis activity is strongly inhibited after pretreatment of cells with anti-NKp44L mAb, confirming that the NK activity is directly correlated with an increase of cell surface expression of NKp44L, in cells treated with the WT peptide ( Figure 6C).
  • kinetic study of the cell surface expression of NKp44L revealed that this receptor was rapidly expressed at the cell surface, indeed after 10 min of treatment with WT peptide, around 10% of CD4+ T cells expressed this protein, and the maximun of expression (approximately 30%) was obtained 4-days after treatment.
  • the very fast cell surface expression of NKp44L suggested an absence of new synthesis of NKp44L, and suggested that this protein was present inside the CD4+ T cells cultured with IL2. This hypothesis was confirmed by an intracellular staining of NKp44L.
  • Figure 6D high expression of NKp44L was detectable inside the cells, and this independently of the presence of peptides.
  • Example 4 Cell surface expression of NKp44L of different human cells As shown on figure 7, the surface expression of NKp44L on K562, Jurkat, and resting PBMC has been tested. The cells were incubated with 1 ⁇ g/ml of anti-NKp44L mAb anti-NKp44L mAb (grey thick line) or with the IgM isotype control (black thin), and analyzed by flow cytometry. It is clearly shown that, contrary to PBMC, tumor cells, like jurkat, and K562 cells express NKp44L on their surface. Exemple 5 Identification of #7.1. an anti-NKp44L mAb that specifically inhibits NKp44- mediated NK lysis.
  • a library of mAbs screened for their capacity to inhibit NK lysis has been tested.
  • the #7.1 mAb revealed an epitope expressed on NKp44L.
  • Specific staining with this mAb was found in HIV- infected U2 cells only, not in uninfected U2 cells (Fig. ⁇ B), and it yielded a level of staining similar to that of the NKp44-lg fusion protein (compare Fig. 8A and 8B).
  • Inhibition of the #7.1 mAb staining by this fusion protein confirmed that #7.1 mAb specificaly interact with a NKp44 ligand (NKp44L) (Fig. 8C).
  • gp41-C146 peptide highly purified peptide (gp41-C146 peptide) (>95%) was linked to the KLH and injected in several rabbits. Serum titres were determined by ELISA on PeptiPlaks. Antibodies were purified by chromatography. NKp44L expression was substantially lower (7.8%) in purified CD4+ T cells from two HIV-1 infected patients that were incubated with purified anti-gp41-C146 polyclonal Ab than in purified and then untreated cells (27.2%) or in those treated with a control Ab (27.9%) (Fig. 9E). This effect was confirmed by the drastic inhibition of NK activity in the presence of the anti-gp41-C146 polyclonal Ab(Fig.9F).
  • HIV-1 RNA in the lamina intestinal of patients with AIDS and gastrointestinal disease. J Infect Dis 1989;159(3):467-71. Garry RF. Potential mechanisms for the cytopathic properties of HIV. AIDS 1989;3(11):683-94. Golding H, Shearer GM, Hillman K, Lucas P, et al. Common epitope in human immunodeficiency virus I (HIV) I-GP41 and HLA class II elicits immunosuppressive antibodies capable of contributing to immune dysfunction in HIV-infected individuals. J Clin Invest 1989;83(4):1430-5. Gong et al., 1994, Leukemia, vol.8 (4):652-658.
  • HIV human immunodeficiency virus I
  • Ho DD Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321 (24): 1621-5.
  • Ho DD Neumann AU, Perelson AS, Chen W, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
  • Hoxie JA Alpers JD, Rackowski JL, Huebner K, et al. Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science 1986;234(4780): 1123-7.
  • Hugin AW Vacchio MS, Morse HC III.
  • T4+ lymphocyte depletion a mechanism for CD4+ (T4) lymphocyte depletion.

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP05715302A 2004-02-06 2005-02-07 Von gp41 abgeleitetes polypeptid, das polypeptid enthaltende impfstoffzusammensetzung sowie verwendungen zur behandlung einer hiv-virusinfektion in einem individuum Withdrawn EP1714153A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05715302A EP1714153A2 (de) 2004-02-06 2005-02-07 Von gp41 abgeleitetes polypeptid, das polypeptid enthaltende impfstoffzusammensetzung sowie verwendungen zur behandlung einer hiv-virusinfektion in einem individuum

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/001106 WO2004070385A1 (en) 2003-02-06 2004-02-06 A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual
PCT/EP2005/001395 WO2005076001A2 (en) 2004-02-06 2005-02-07 A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
EP05715302A EP1714153A2 (de) 2004-02-06 2005-02-07 Von gp41 abgeleitetes polypeptid, das polypeptid enthaltende impfstoffzusammensetzung sowie verwendungen zur behandlung einer hiv-virusinfektion in einem individuum

Publications (1)

Publication Number Publication Date
EP1714153A2 true EP1714153A2 (de) 2006-10-25

Family

ID=36997402

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05715302A Withdrawn EP1714153A2 (de) 2004-02-06 2005-02-07 Von gp41 abgeleitetes polypeptid, das polypeptid enthaltende impfstoffzusammensetzung sowie verwendungen zur behandlung einer hiv-virusinfektion in einem individuum

Country Status (1)

Country Link
EP (1) EP1714153A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
WO1988008429A1 (en) * 1987-04-24 1988-11-03 Biogen N.V. Immunotherapeutic methods and compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
WO1988008429A1 (en) * 1987-04-24 1988-11-03 Biogen N.V. Immunotherapeutic methods and compositions

Similar Documents

Publication Publication Date Title
Fantini et al. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor.
Boudet et al. Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection.
Giulian et al. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes.
Haigwood et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile
Tyler et al. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.
EP1152012B1 (de) CD8 Tuberkulose Impfstoffe
Nardelli et al. CD4+ blood lymphocytes are rapidly killed in vitro by contact with autologous human immunodeficiency virus-infected cells.
US20090136533A1 (en) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
EP0609305A1 (de) Mit multipler sklerose (ms) verbundener typ-c ähnliches menschliches retroviru
CA2558733C (en) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
Dreyer et al. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy
US10174080B2 (en) Compositions for preventing and/or treating an infection by an HIV-1 virus
Thomas et al. Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of HIV-1 infection cycle
Kameoka et al. Protease-defective, gp120-containing human immunodeficiency virus type 1 particles induce apoptosis more efficiently than does wild-type virus or recombinant gp120 protein in healthy donor-derived peripheral blood T cells
US20070122415A1 (en) Compound and method for suppressing retroviral replication
US20170128564A1 (en) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
US20070092525A1 (en) Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
EP1714153A2 (de) Von gp41 abgeleitetes polypeptid, das polypeptid enthaltende impfstoffzusammensetzung sowie verwendungen zur behandlung einer hiv-virusinfektion in einem individuum
WO2010040853A1 (en) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method
Margolin et al. High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys
JPH09510603A (ja) Ｈｉｖ−１エンベロープ糖タンパクに媒介された膜融合の共鳴エネルギートランスファーに基づく試験を用いるための方法、およびこれを実施するためのキット
VIEILLARD et al. Patent 2519012 Summary
Achour et al. A binding assay to identify HIV (LAV) target cells
US5580772A (en) Association between a novel human intracisternal A-type retroviral particle-type II (HIAP-II) and idiopathic CD4+ T-lymphocytopenia (ICL)
Kameoka et al. Induction of apoptosis by protease-defective particle preparations of human immunodeficiency virus type 1 is specific to a subset of U937-derived subclones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060906

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20091028

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAX Date of receipt of notice of appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDNOA2E

APAZ Date of receipt of statement of grounds of appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDNOA3E

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180901